Apellis Pharmaceuticals Inc (APLS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Apellis Pharmaceuticals Inc (APLS) has a cash flow conversion efficiency ratio of -0.147x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-60.97 Million) by net assets ($414.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Apellis Pharmaceuticals Inc to measure how many days the company can operate on defensive assets alone.
Apellis Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Apellis Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Apellis Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Apellis Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Delek Automotive Systems Ltd
TA:DLEA
|
0.164x |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
-0.029x |
|
Tianjin Jieqiang Power Equipment Co
SHE:300875
|
-0.007x |
|
eQ Oyj
HE:EQV1V
|
0.103x |
|
Ribbon Communications Inc
NASDAQ:RBBN
|
-0.052x |
|
Changshu Ruite Electric Co Ltd
SHE:300600
|
0.998x |
|
Zhanjiang Guolian Aquatic Products
SHE:300094
|
0.014x |
|
SOLiD Inc
KQ:050890
|
-0.030x |
Annual Cash Flow Conversion Efficiency for Apellis Pharmaceuticals Inc (2013–2025)
The table below shows the annual cash flow conversion efficiency of Apellis Pharmaceuticals Inc from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Apellis Pharmaceuticals Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $370.15 Million | $45.33 Million | 0.122x | +131.85% |
| 2024-12-31 | $228.54 Million | $-87.87 Million | -0.384x | +87.43% |
| 2023-12-31 | $194.52 Million | $-594.74 Million | -3.057x | -1.10% |
| 2022-12-31 | $169.87 Million | $-513.75 Million | -3.024x | -6.69% |
| 2021-12-31 | $198.66 Million | $-563.13 Million | -2.835x | -261.30% |
| 2020-12-31 | $204.56 Million | $-160.49 Million | -0.785x | +87.28% |
| 2019-12-31 | $34.23 Million | $-211.13 Million | -6.168x | -656.56% |
| 2018-12-31 | $160.97 Million | $-131.24 Million | -0.815x | -160.61% |
| 2017-12-31 | $148.94 Million | $-46.60 Million | -0.313x | +71.37% |
| 2016-12-31 | $23.79 Million | $-26.00 Million | -1.093x | -102.71% |
| 2015-12-31 | $34.98 Million | $-18.86 Million | -0.539x | +28.33% |
| 2014-12-31 | $13.22 Million | $-9.95 Million | -0.752x | +1.25% |
| 2013-12-31 | $4.52 Million | $-3.44 Million | -0.762x | -- |
About Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy… Read more